Donor CD4+ T-cell production of tumor necrosis factor alpha significantly contributes to the early proinflammatory events of graft-versus-host disease

Experimental Hematology

Volumn 35, Issue 1, 2007, Pages 155-163

  Ewing, Patricia ^a   Miklos, Sandra ^a   Olkiewicz, Krystyna M ^b   Müller, Gunnar ^a   Andreesen, Reinhard ^a   Holler, Ernst ^a   Cooke, Kenneth R ^b   Hildebrandt, Gerhard C ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR NECROSIS FACTOR ALPHA;

ALLOGENEIC STEM CELL TRANSPLANTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW TRANSPLANTATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DONOR; FEMALE; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HOST CELL; INFLAMMATION; IRRADIATION; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RECIPIENT; SPLEEN CELL; WILD TYPE;

ANIMALS; BONE MARROW TRANSPLANTATION; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; GRAFT VS HOST DISEASE; INFLAMMATION; KINETICS; MICE; MICE, INBRED STRAINS; SURVIVAL RATE; T-LYMPHOCYTES; TISSUE DONORS; TRANSPLANTATION, HOMOLOGOUS; TRANSPLANTATION, ISOGENEIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33845805735     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2006.09.012     Document Type: Article

References (64)

1. Ferrara J.L., and Deeg H.J. Graft-versus-host disease. N Engl J Med 324 (1991) 667-674
2. Storb R., Deeg H.J., Whitehead J., et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 314 (1986) 729-735
3. Storb R., Deeg H.J., Fisher L., et al. Cyclosporine v methotrexate for graft-v-host disease prevention in patients given marrow grafts for leukemia: long-term follow-up of three controlled trials. Blood 71 (1988) 293-298
4. Storb R., Deeg H.J., Pepe M., et al. Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: long-term follow-up of a controlled trial. Blood 73 (1989) 1729-1734
5. Storb R., Deeg H.J., Pepe M., et al. Graft-versus-host disease prevention by methotrexate combined with cyclosporin compared to methotrexate alone in patients given marrow grafts for severe aplastic anaemia: long-term follow-up of a controlled trial. Br J Haematol 72 (1989) 567-572
6. Ratanatharathorn V., Nash R.A., Przepiorka D., et al. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood 92 (1998) 2303-2314
7. Nash R.A., Antin J.H., Karanes C., et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood 96 (2000) 2062-2068
8. Schmaltz C., Alpdogan O., Kappel B.J., et al. T cells require TRAIL for optimal graft-versus-tumor activity. Nat Med 8 (2002) 1433-1437
9. Schmaltz C., Alpdogan O., Muriglan S.J., et al. Donor T cell-derived TNF is required for graft-versus-host disease and graft-versus-tumor activity after bone marrow transplantation. Blood 101 (2003) 2440-2445
10. Via C., Nguyen P., Shustov A., Drappa J., and Elkon K. A major role for the Fas pathway in acute graft-versus-host disease. J Immunol 157 (1996) 5387-5393
11. Hattori K., Hirano T., Miyajima H., et al. Differential effects of anti-Fas ligand and anti-tumor necrosis factor-a antibodies on acute graft-versus-host disease pathologies. Blood 91 (1998) 4051-4055
12. Nestel F.P., Price K.S., Seemayer T.A., and Lapp W.S. Macrophage priming and lipopolysaccharide-triggered release of tumor necrosis factor alpha during graft-versus-host disease. J Exp Med 175 (1992) 405-413
13. Teshima T., Ordemann R., Reddy P., et al. Acute graft-versus-host disease does not require alloantigen expression on host epithelium. Nat Med 8 (2002) 575-581
14. Brown G.R., Lindberg G., Meddings J., Silva M., Beutler B., and Thiele D. Tumor necrosis factor inhibitor ameliorates murine intestinal graft-versus-host disease. Gastroenterology 116 (1999) 593-601
15. Hill G.R., and Ferrara J.L. The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation. Blood 95 (2000) 2754-2759
16. Hill G.R., Crawford J.M., Cooke K.R., Brinson Y.S., Pan L., and Ferrara J.L. Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines. Blood 90 (1997) 3204-3213
17. Hill G.R., Teshima T., Rebel V.I., et al. The p55 TNF-alpha receptor plays a critical role in T cell alloreactivity. J Immunol 164 (2000) 656-663
18. Speiser D.E., Bachmann M.F., Frick T.W., et al. TNF receptor p55 controls early acute graft-versus-host disease. J Immunol 158 (1997) 5185-5190
19. Piguet P.F., Grau G.E., Allet B., and Vassalli P.J. Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-versus-host disease. J Exp Med 166 (1987) 1280-1289
20. Cooke K.R., Hill G.R., Crawford J.M., et al. Tumor necrosis factor- alpha production to lipopolysaccharide stimulation by donor cells predicts the severity of experimental acute graft-versus-host disease. J Clin Invest 102 (1998) 1882-1891
21. Remberger M., Ringden O., and Markling L. TNF alpha levels are increased during bone marrow transplantation conditioning in patients who develop acute GVHD. Bone Marrow Transplant 15 (1995) 99-104
22. Holler E., Kolb H.J., Moller A., et al. Increased serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation. Blood 75 (1990) 1011-1016
23. Holler E., Kolb H.J., Hintermeier-Knabe R., et al. The role of tumor necrosis factor alpha in acute graft-versus-host disease and complications following allogeneic bone marrow transplantation. Transplant Proc 25 (1993) 1234-1236
24. Brockhaus M., Schoenfeld H.J., Schlaeger E.J., Hunziker W., Lesslauer W., and Loetscher H. Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies. Proc Natl Acad Sci U S A 87 (1990) 3127-3131
25. Loetscher H., Pan Y.C., Lahm H.W., et al. Molecular cloning and expression of the human 55 kd tumor necrosis factor receptor. Cell 61 (1990) 351-359
26. Dembic Z., Loetscher H., Gubler U., et al. Two human TNF receptors have similar extracellular, but distinct intracellular, domain sequences. Cytokine 2 (1990) 231-237
27. Lewis M., Tartaglia L.A., Lee A., et al. Cloning and expression of cDNAs for two distinct tumor necrosis factor receptors demonstrate on receptor is species-specific. Proc Natl Acad Sci U S A 88 (1991) 2830-2834
28. Schall T.J., Lewis M., Koller K.J., et al. Molecular cloning and expression of a receptor for human tumor necrosis factor. Cell 61 (1990) 361-370
29. Antin J.H., Weisdorf D., Neuberg D., et al. Interleukin-1 blockade does not prevent acute graft-versus-host disease: results of a randomized, double-blind, placebo-controlled trial of interleukin-1 receptor antagonist in allogeneic bone marrow transplantation. Blood 100 (2002) 3479-3482
30. Pfeffer K., Matsuyama T., Kundig T.M., et al. Mice deficient for the 55kD tumor necrosis factor receptor are resistant to endotoxin shock, yet succumb to L. monocytogenes infection. Cell 73 (1993) 457-467
31. Pasparakis M., Alexopoulou L., Episkopou V., and Kollias G. Immune and inflammatory responses in TNF alpha-deficient mice: a critical requirement for TNF alpha in the formation of primary B cell follicles, follicular dendritic cell networks and germinal centers, and in the maturation of the humoral immune response. J Exp Med 184 (1996) 1397-1411
32. Hildebrandt G.C., Olkiewicz K.M., Corrion L.A., et al. Donor-derived TNF-alpha regulates pulmonary chemokine expression and the development of idiopathic pneumonia syndrome after allogeneic bone marrow transplantation. Blood 104 (2004) 586-593
33. Cooke K., Gerbitz A., Hill G., et al. LPS antagonism reduces graft-versus-host disease and preserves graft-versus-leukemia activity after experimental bone marrow transplantation. J Clin Invest 107 (2001) 1581-1589
34. Cooke K.R., Kobzik L., Martin T.R., et al. An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation. I. The roles of minor H antigens and endotoxin. Blood 88 (1996) 3230-3239
35. Grell M., Wajant H., Zimmermann G., and Scheurich P. The type 1 receptor (CD120a) is the high-affinity receptor for soluble tumor necrosis factor. Proc Natl Acad Sci U S A 95 (1998) 570-575
36. Tartaglia L.A., Ayres T.M., Wong G.H., and Goeddel D.V. A novel domain within the 55 kd TNF receptor signals cell death. Cell 74 (1993) 845-853
37. Tartaglia L.A., Rothe M., Hu Y.F., and Goeddel D.V. Tumor necrosis factor's cytotoxic activity is signaled by the p55 TNF receptor. Cell 73 (1993) 213-216
38. Neumann B., Machleidt T., Lifka A., et al. Crucial role of 55 kilodalton TNF receptor in TNFa induced adhesion molecule expression and leukocyte organ infiltration. J Immunol 156 (1996) 1587-1593
39. Peschon J.J., Torrance D.S., Stocking K.L., et al. TNF receptor-deficient mice reveal divergent roles for p55 and p75 in several models of inflammation. J Immunol 160 (1998) 943-952
40. Tartaglia L.A., and Goeddel D.V. Two TNF receptors. Immunol Today 13 (1992) 151-153
41. Reddy P. Pathophysiology of acute graft-versus-host disease. Hematol Oncol 21 (2003) 149-161
42. Laster S.M., Wood J.G., and Gooding L.R. Tumor necrosis factor can induce both apoptic and necrotic forms of cell lysis. J Immunol 141 (1988) 2629-2634
43. Holler E., Kolb H.J., Mittermueller J., et al. Modulation of acute graft-versus-host disease after allogeneic bone marrow transplantation by tumor necrosis factor a (TNFa) release in the course of pretransplant conditioning: role of conditioning regimens and prophylactic application of a monoclonal antibody neutralizing human TNFa (MAK 195F). Blood 86 (1995) 890-899
44. Perreault C., Pelletier M., Belanger R., et al. Persistence of host Langerhans cells following allogeneic bond marrow transplantation: Possible relationship with acute graft-versus-host disease. Br J Haematol 60 (1985) 253-260
45. Nakata K., Gotoh H., Watanabe J., et al. Augmented proliferation of human alveolar macrophages after allogeneic bone marrow transplantation. Blood 93 (1999) 667-673
46. Hildebrandt G.C., Duffner U.A., Olkiewicz K.M., et al. A critical role for CCR2/MCP-1 interactions in the development of idiopathic pneumonia syndrome after allogeneic bone marrow transplantation. Blood 103 (2004) 2417-2426
47. Matute-Bello G., Lee J.S., Frevert C.W., et al. Optimal timing to repopulation of resident alveolar macrophages with donor cells following total body irradiation and bone marrow transplantation in mice. J Immunol Methods 292 (2004) 25-34
48. Welniak L.A., Kuprash D.V., Tumanov A.V., et al. Peyer patches are not required for acute graft-versus-host disease after myeloablative conditioning and murine allogeneic bone marrow transplantation. Blood 107 (2006) 410-412
49. Gifford G.E., and Lohmann-Matthes M.-L. Gamma interferon priming of mouse and human macrophages for induction of tumor necrosis factor production by bacterial lipopolysaccharide. J Natl Cancer Inst 78 (1987) 121-124
50. Rothe J., Lesslauer W., Lotscher H., et al. Mice lacking the tumour necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes. Nature 364 (1993) 798-802
51. Rothe J., Mackay F., Bluethmann H., Zinkernagel R., and Lesslauer W. Phenotypic analysis of TNFR1-deficient mice and characterization of TNFR1-deficient fibroblasts in vitro. Circ Shock 44 (1994) 51-56
52. Sheehan K.C., Pinckard J.K., Arthur C.D., Dehner L.P., Goeddel D.V., and Schreiber R.D. Monoclonal antibodies specific for murine p55 and p75 tumor necrosis factor receptors: identification of a novel in vivo role for p75. J Exp Med 181 (1995) 607-617
53. Brown G.R., and Thiele D.L. Enhancement of MHC class I-stimulated alloresponses by TNF/TNF receptor (TNFR)1 interactions and of MHC class II-stimulated alloresponses by TNF/TNFR2 interactions. Eur J Immunol 30 (2000) 2900-2907
54. Ferrara J.L. Cytokine dysregulation as a mechanism of graft-versus-host disease. Curr Opin Immunol 5 (1993) 794-799
55. Antin J.H., and Ferrara J.L.M. Cytokine dysregulation and acute graft-versus-host disease. Blood 80 (1992) 2964-2968
56. Ferrara J.L.M., Abhyankar S., and Gilliland D.G. Cytokine storm of graft-versus-host disease: a critical effector role for interleukin-1. Transplant Proc 25 (1993) 1216-1217
57. Via C.S., Nguyen P., Shustov A., Drappa J., and Elkon K.B. A major role for the Fas pathway in acute graft-versus-host disease. J Immunol 157 (1996) 5387-5393
58. Teshima T., Hill G.R., Pan L., et al. IL-11 separates graft-versus-leukemia effects from graft-versus-host disease after bone marrow transplantation. J Clin Invest 104 (1999) 317-325
59. Min C.K., Maeda Y., Lowler K., et al. Paradoxical effects of interleukin-18 on the severity of acute graft-versus-host disease mediated by CD4+ and CD8+ T-cell subsets after experimental allogeneic bone marrow transplantation. Blood 104 (2004) 3393-3399
60. Monastra G., Cabrelle A., Zambon A., et al. Membrane form of TNF alpha induces both cell lysis and apoptosis in susceptible target cells. Cell Immunol 171 (1996) 102-110
61. Kinkhabwala M., Sehajpal P., Skolnik E., et al. A novel addition to the T cell repertory. Cell surface expression of tumor necrosis factor/cachectin by activated normal human T cells. J Exp Med 171 (1990) 941-946
62. Zhao M.Q., Stoler M.H., Liu A.N., et al. Alveolar epithelial cell chemokine expression triggered by antigen-specific cytolytic CD8(+) T cell recognition. J Clin Invest 106 (2000) R49-R58
63. Cooke K.R., Hill G.R., Gerbitz A., et al. Hyporesponsiveness of donor cells to lipopolysaccharide stimulation reduces the severity of experimental idiopathic pneumonia syndrome: potential role for a gut-lung axis of inflammation. J Immunol 165 (2000) 6612-6619
64. Uberti J.P., Ayash L., Ratanatharathorn V., et al. Pilot trial on the use of etanercept and methylprednisolone as primary treatment for acute graft-versus-host disease. Biol Blood Marrow Transplant 11 (2005) 680-687